Transsplenic Arterial Radioembolization of Hepatic Metastases in a Patient with Celiac Artery Occlusion

A 75-year-old man with isolated liver metastasis from prostate cancer refractory to systemic chemotherapy was referred for radioembolization (Fig 1). The chronically occluded celiac artery could not be traversed. Retrograde cannulation of the gastroduodenal artery was performed via the superior mesenteric artery using a 0.021-inch Direxion microcatheter (Boston Scientific, Marlborough, Massachusetts) and 0.016-inch Fathom wire (Boston Scientific) with successful catheterization of the right hepatic artery (Figs 2 –4).
Source: Journal of Vascular and Interventional Radiology : JVIR - Category: Radiology Authors: Tags: Extreme IR Source Type: research

Related Links:

CONCLUSION: These updated French guidelines will contribute to increase the level of urological care for the diagnosis and treatment for prostate cancer. PMID: 31610875 [PubMed - in process]
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
Publication date: Available online 15 October 2019Source: Social Science &MedicineAuthor(s): A. Angelis, M. Linch, G. Montibeller, T. Molina Lopez, A. Zawada, K. Orzel, F. Arickx, J. Espin, P. KanavosAbstractMultiple Criteria Decision Analysis (MCDA) has emerged as a likely methodology for Health Technology Assessment (HTA). However limited empirical evidence is available on its use by decision-makers and only as part of single-setting exercises, without cross-county studies available. This pilot study applies the Advance Value Framework (AVF), an MCDA methodology for HTA based on multi-attribute value theory, through ...
Source: Social Science and Medicine - Category: Psychiatry & Psychology Source Type: research
We previously showed that n-3-long-chain polyunsaturated fatty acids (n-3 LCPUFA) can enhance apoptosis in breast cancer cells (BC) and that docosahexaenoic acid (DHA; 22:6n-3) can improve the efficacy of chemotherapy drugs commonly used in breast and prostate cancer treatment [1,2]. Suggestions that n-6 LCPUFA, that predominate in Western diets, can elicit pro-cancer effects, as observed in both cell studies and in animal models of cancer [3], instead of the anticancer effects attributed to n-3 LCPUFA, are still controversial.
Source: Prostaglandins, Leukotrienes and Essential Fatty Acids - Category: Biomedical Science Authors: Source Type: research
Madam — Due to the upfront use of docetaxel chemotherapy in patients with metastatic prostate cancer, there is a therapeutic conundrum for subsequent treatment at the time of progressive disease. Cabazitaxel has been established as a second-line chemotherapy option by the TROPIC trial [1], but concerns regarding toxicity mean it has not been adopted into widespread use. However, improved quality of life and modest toxicity have been reported by a recent UK early access programme [2]. There will probably be a renewed interest in both docetaxel and cabazitaxel chemotherapy in patients with metastati c castrate-resistan...
Source: Clinical Oncology - Category: Radiology Authors: Tags: Letter Source Type: research
AbstractPurposeTo provide a snapshot of toxicities and oncologic outcomes of Abiraterone (AA) and Enzalutamide (EZ) in a chemo-na ïve metastatic castration-resistant prostate cancer (mCPRC) population from a longitudinal real-life multicenter cohort.MethodsWe prospectively collected data on chemo-na ïve mCRPC patients treated with AA or EZ. Primary outcomes were PSA response, oncologic outcomes and toxicity profile. The Kaplan–Meier method was used to compare differences in terms of progression-free survival (PFS) between AA vs EZ and high- vs low-volume disease cohorts. Univariable and mult ivariable Cox r...
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
Conclusion: TB of the prostate may present like cancer prostate with raised serum PSA and suspicious prostate on DRE; hence, a high index of suspicion with a wide range of investigations may be required to achieve a complete diagnosis of prostatic TB.
Source: Urology Annals - Category: Urology & Nephrology Authors: Source Type: research
CONCLUSION: The presence of the primary prostate tumor seems to play a detrimental role in mCRPC patients undergoing 223Ra treatment in absence of other concomitant anticancer therapy. On the other hand a previous RP might play a protective role. PMID: 31601517 [PubMed - as supplied by publisher]
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Tags: Urol Oncol Source Type: research
This study evaluated the impact of cumulative corticosteroid exposure on the risk of developing specific adverse events in men with CRPC.MethodsData were obtained from administrative claims databases. Adult chemotherapy-na ïve men who initiated CRPC treatment following surgical or medical castration were selected. Patients were grouped into four cohorts based on cumulative corticosteroid dose: no exposure, low exposure (  2.0 g). Time to each adverse event was assessed using Kaplan–Meier analyses and time-dependent Cox proportional hazard models, adjusting for baseline characteristics.ResultsOverall,...
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research
Men with advanced prostate cancer who stop responding to targeted hormone therapy but are then treated with modern chemotherapy have better survival rates than those given a second targeted treatment, a study published in the New England Journal of Medicine has shown.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
AbstractBackgroundHigh levels of adenosine present in the tumor microenvironment have direct immunosuppressive impact on T-cell function and activation. AB928, a selective, small-molecule dual A2aR/A2bR antagonist, potently blocks the effects of adenosine and, in combination with chemotherapy or anti-PD-1, may have a more profound effect on reactivating anti-tumor immunity.MethodsFour phase I, open-label, disease-specific platform studies assessing the safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of AB928 in combination with chemotherapy (chemo) or AB122. In dose escalation (3  +&thins...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Gastroenterology | Liver | Prostate Cancer | Radiology | Urology & Nephrology